Advanced Solid Tumours Clinical Trial
Official title:
Safety of Extended Use of ModraDoc006/r in Patients With Advanced Solid Tumours
This is a study for extended use of ModraDoc006/r in patients with advanced solid tumours, available after completed treatment in one of the phase I trials with ModraDoc006/r. The primary goal is to explore the safety of extended use.
This is an open label extended use programme, designed to make extended use treatment with weekly ModraDoc006/r available for patients who completed treatment in one of the phase I trials with ModraDoc006/r, who might have clinical benefit of continued treatment with the oral docetaxel formulation. Patients will receive oral docetaxel (as ModraDoc006 10 mg tablets) and ritonavir (100 mg tablet) once- or bi-daily, once a week in a fasted condition. Treatment can be continued weekly as long as the patient experiences clinical benefit from the treatment as judged by the treating oncologist, unless unacceptable toxicity despite dose modifications and supportive measures occurs. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05514132 -
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
|
Phase 1 | |
Terminated |
NCT04949425 -
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT05537051 -
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT02579226 -
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01668550 -
A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01058538 -
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02588105 -
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
Not yet recruiting |
NCT06380816 -
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01585701 -
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor
|
Phase 1 | |
Completed |
NCT03101839 -
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
|
Phase 1 | |
Active, not recruiting |
NCT02389842 -
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
|
Phase 1 | |
Terminated |
NCT01581060 -
Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
|
Phase 1/Phase 2 | |
Terminated |
NCT04959266 -
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
|
Phase 1 | |
Completed |
NCT04462952 -
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
|
Phase 1 | |
Active, not recruiting |
NCT03518606 -
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02430311 -
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
|
Phase 1 | |
Terminated |
NCT01859351 -
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
|
Phase 1 | |
Completed |
NCT01163903 -
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
|
Phase 1 | |
Recruiting |
NCT05804526 -
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
|
Phase 1/Phase 2 |